Titelbild

Leadership Team

Topas Therapeutics is led by a highly qualified team with scientific depth and decades of experience in drug development and operational management.

 
Portrait

Timm Jessen, CEO

Timm is co-founder and CEO of Topas Therapeutics. He has held leading positions in Sanofi (formerly Hoechst Marion Roussel) and Evotec. In his independent career he has founded several companies, provided management and board expertise to biotech firms and advised private and institutional investors. Timm has studied chemistry and received his PhD in biochemistry, he spent his academic time in Kiel, Munich, Cambridge/UK and Boston.

 
Portrait

Timm Jessen, CEO

Timm is co-founder and CEO of Topas Therapeutics. He has held leading positions in Sanofi (formerly Hoechst Marion Roussel) and Evotec. In his independent career he has founded several companies, provided management and board expertise to biotech firms and advised private and institutional investors. Timm has studied chemistry and received his PhD in biochemistry, he spent his academic time in Kiel, Munich, Cambridge/UK and Boston.

 
Portrait

Johannes Pohlner, COO

John is co-founder and COO of Topas Therapeutics GmbH, focussing on the translation of academic innovation into industrial application. This focus also applies for his previous key roles executed over the last two decades at Bionamics GmbH, Evotec Neurosciences GmbH and Evotec AG. Before that he built up a broad scientific basis in biology at major research institutes in Germany, received the PhD in biology at Heidelberg University and gained his habilitation at Tübingen University.

 
Portrait

Johannes Pohlner, COO

John is co-founder and COO of Topas Therapeutics GmbH, focussing on the translation of academic innovation into industrial application. This focus also applies for his previous key roles executed over the last two decades at Bionamics GmbH, Evotec Neurosciences GmbH and Evotec AG. Before that he built up a broad scientific basis in biology at major research institutes in Germany, received the PhD in biology at Heidelberg University and gained his habilitation at Tübingen University.

 
Portrait

Rupert Sandbrink, Chief Development Officer / Chief Medical Officer

Rupert is a member of Topas’ Executive Management Team and leading Topas‘ clinical development and regulatory affairs. He is a Board-certified clinical pharmacologist with almost 20 years of experience who previously held senior management positions in clinical development at Forward Pharma A/S and Bayer (and before, at Schering AG). Rupert received his medical training and his Ph.D. in molecular biology at the University of Heidelberg, and he serves as a lecturer and guest scientist at the University of Duesseldorf, Department of Neurology.

 
Portrait

Rupert Sandbrink, Chief Development Officer / Chief Medical Officer

Rupert is a member of Topas’ Executive Management Team and leading Topas‘ clinical development and regulatory affairs. He is a Board-certified clinical pharmacologist with almost 20 years of experience who previously held senior management positions in clinical development at Forward Pharma A/S and Bayer (and before, at Schering AG). Rupert received his medical training and his Ph.D. in molecular biology at the University of Heidelberg, and he serves as a lecturer and guest scientist at the University of Duesseldorf, Department of Neurology.

 
Portrait

Reinaldo Digigow, Head of Nanotechnology

Reinaldo was trained as a pharmacist and biochemist and received his PhD from the University of Fribourg (CH). He has worked in pharmaceutical companies and analytical chemical labs in Brazil and Europe. Before joining Topas Therapeutics Reinaldo was with Takeda Pharmaceuticals as Lab Head Analytical Development, CMC Center Europe. At Topas he focuses on nanoparticle design and synthesis, on analytics and on the strategy and execution of the drug product development.

 
Portrait

Reinaldo Digigow, Head of Nanotechnology

Reinaldo was trained as a pharmacist and biochemist and received his PhD from the University of Fribourg (CH). He has worked in pharmaceutical companies and analytical chemical labs in Brazil and Europe. Before joining Topas Therapeutics Reinaldo was with Takeda Pharmaceuticals as Lab Head Analytical Development, CMC Center Europe. At Topas he focuses on nanoparticle design and synthesis, on analytics and on the strategy and execution of the drug product development.

 
Portrait

Sabine Fleischer, Head of Translational Medicine

Sabine studied medicine at the Universities of Giessen, Göttingen and Würzburg. As a scholar of the German Research Foundation she was trained in Molecular Biology and Immunology at the Institute of Biochemistry in Munich and the Basel Institute for Immunology and worked as a postdoc at the Institute of Immunology in Ulm. Since 2009 she has been Scientific Coordinator of the Institute of Neuroimmunology and Multiple Sclerosis in Hamburg focussing on translational research projects and early clinical MS studies in the framework of the research consortium NEU². In November 2015, she joined Topas as Head of Translational Medicine.

 
Portrait

Sabine Fleischer, Head of Translational Medicine

Sabine studied medicine at the Universities of Giessen, Göttingen and Würzburg. As a scholar of the German Research Foundation she was trained in Molecular Biology and Immunology at the Institute of Biochemistry in Munich and the Basel Institute for Immunology and worked as a postdoc at the Institute of Immunology in Ulm. Since 2009 she has been Scientific Coordinator of the Institute of Neuroimmunology and Multiple Sclerosis in Hamburg focussing on translational research projects and early clinical MS studies in the framework of the research consortium NEU². In November 2015, she joined Topas as Head of Translational Medicine.

 
Portrait

Barbara Metzler, Head of Biology

Barbara has a long-standing interest and over 25 years of experience in immune tolerance and immune regulation research in academia and industry. Before joining Topas Therapeutics she led a research lab and numerous projects in autoimmunity and transplantation at Novartis. Her postgraduate and postdoctoral studies were concerned with T cell regulation, with an early focus on peptide-induced tolerance in models of autoimmunity. Barbara has a BSc (Hons) in Biochemistry from Edinburgh University and a PhD in Immunology from the University of Cambridge.

 
Portrait

Barbara Metzler, Head of Biology

Barbara has a long-standing interest and over 25 years of experience in immune tolerance and immune regulation research in academia and industry. Before joining Topas Therapeutics she led a research lab and numerous projects in autoimmunity and transplantation at Novartis. Her postgraduate and postdoctoral studies were concerned with T cell regulation, with an early focus on peptide-induced tolerance in models of autoimmunity. Barbara has a BSc (Hons) in Biochemistry from Edinburgh University and a PhD in Immunology from the University of Cambridge.